Roivant Sciences Ltd Insider Trading

ROIV

Last 12 months

Insiders sold $639M and bought nothing on the open market.

25% of the selling was scheduled in advance under 10b5-1 plans. Director Keith S Manchester sold $56.4M on Jun 30, 9.6% of their stake, outside a plan. The last open-market buy by an executive or director was in Sep 2025.

Net open-market

−$639M

0 buys · 41 sales

Under a 10b5-1 plan

25%

of the value sold

Insiders who bought / sold

0 / 10

executives and directors

Last open-market buy

Sep 2025

Sep 18, 2025

Get an email when ROIV's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 28	Eric Venker President & Immunovant CEO	Sold10b5-1 plan	200,000	$36.59	$7.32M	14%	Form 4
Oct 20	Eric Venker President & Immunovant CEO	Sold10b5-1 plan 2 parts	200,000	$35.11 average	$7.02M	13%	Form 4
Oct 1	Melissa B Epperly Director	Sold10b5-1 plan 2 parts	17,750	$36.10 average	641K	54%	Form 4
Sep 30	Eric Venker President & Immunovant CEO	Sold10b5-1 plan	200,000	$36.62	$7.32M	11%	Form 4
Sep 15	Melissa B Epperly Director	Sold10b5-1 plan 2 parts	4,938	$39.74 average	196K	33%	Form 4
Sep 15	Meghan Fitzgerald Director	Sold10b5-1 plan 2 parts	5,112	$39.74 average	203K	12%	Form 4
Sep 8	Meghan Fitzgerald Director	Sold10b5-1 plan	20,000	$39.90	798K	32%	Form 4
Aug 28	Eric Venker President & Immunovant CEO	Sold10b5-1 plan 2 parts	200,000	$35.77 average	$7.15M	11%	Form 4
Aug 19 – 21	Mayukh Sukhatme President & CIO	SoldNo plan 3 parts	335,174	$36.88 average	$12.4M	1.8%	Form 4
Aug 14 – 18	Mayukh Sukhatme President & CIO	SoldNo plan 4 parts	664,826	$36.34 average	$24.2M	3.4%	Form 4
Jul 27	Eric Venker President & Immunovant CEO	Sold10b5-1 plan	200,000	$34.95	$6.99M	11%	Form 4
Jun 30	Meghan Fitzgerald Director	Sold10b5-1 plan	10,000	$34.90	349K	19%	Form 4
Jun 26 – 30	Keith S Manchester Director	SoldNo plan 6 parts	1,638,163	$34.46 average	$56.4M	9.6%	Form 4
Jun 26 – 30	Daniel Allen Gold Director	SoldNo plan 5 parts	1,438,163	$34.32 average	$49.4M	9.5%	Form 4
Jun 26 – 30	QVT Financial LP Large holder	SoldNo plan 5 parts	1,438,163	$34.32 average	$49.4M	9.5%	Form 4
Jun 29	Melissa B Epperly Director	Sold10b5-1 plan 2 parts	17,750	$34.38 average	610K	52%	Form 4
Jun 25 – 26	Mayukh Sukhatme President & CIO	SoldNo plan 2 parts	1,000,000	$34.11 average	$34.1M	5.1%	Form 4
Jun 24	Eric Venker President & Immunovant CEO	Sold10b5-1 plan 2 parts	200,000	$33.16 average	$6.63M	11%	Form 4
May 22	Eric Venker President & Immunovant CEO	Sold10b5-1 plan	200,000	$30.27	$6.05M	11%	Form 4
Apr 20	Eric Venker President & Immunovant CEO	Sold10b5-1 plan	200,000	$29.59	$5.92M	11%	Form 4
Apr 16	Matthew Gline CEO	SoldNo plan	289,774	$29.16	$8.45M	1.7%	Form 4
Apr 8	Jennifer Humes Chief Accounting Officer	SoldNo plan	13,538	$28.37	384K	14%	Form 4
Mar 26	Meghan Fitzgerald Director	SoldNo plan	70,000	$27.45	$1.92M	62%	Form 4
Mar 17	Eric Venker President & Immunovant CEO	Sold10b5-1 plan	200,000	$28.24	$5.65M	11%	Form 4
Mar 16	Melissa B Epperly Director	SoldNo plan	41,861	$28.68	$1.2M	73%	Form 4
Feb 19 – 23	Frank Torti President and Vant Chair	Sold10b5-1 plan 3 parts	3,000,000	$27.35 average	$82M	18%	Form 4
Feb 13	Eric Venker President & Immunovant CEO	Sold10b5-1 plan	200,000	$26.49	$5.3M	11%	Form 4
Feb 11 – 13	Keith S Manchester Director	SoldNo plan 5 parts	1,225,784	$26.64 average	$32.7M	7.5%	Form 4
Feb 11 – 13	Daniel Allen Gold Director	SoldNo plan 5 parts	1,225,784	$26.64 average	$32.7M	7.5%	Form 4
Feb 11 – 13	QVT Financial LP Large holder	SoldNo plan 5 parts	1,225,784	$26.64 average	$32.7M	7.5%	Form 4
Feb 9	Mayukh Sukhatme President & CIO	SoldNo plan	339,441	$26.47	$8.99M	1.8%	Form 4
Jan 12	Eric Venker President & Immunovant CEO	Sold10b5-1 plan	200,000	$21.92	$4.38M	11%	Form 4
Dec 29, 2025 – Dec 31, 2025	Mayukh Sukhatme President & CIO	SoldNo plan 2 parts	1,330,868	$21.72 average	$28.9M	6.6%	Form 4
Dec 23, 2025 – Dec 24, 2025	Eric Venker President & Immunovant CEO	SoldNo plan 2 parts	275,000	$22.47 average	$6.18M	14%	Form 4
Dec 23, 2025	Richard Pulik CFO	SoldNo plan 2 parts	406,731	$22.43 average	$9.12M	63%	Form 4
Dec 17, 2025	Mayukh Sukhatme President & CIO	SoldNo plan	26,831	$23.09	620K	0.1%	Form 4
Dec 16, 2025 – Dec 17, 2025	Daniel Allen Gold Director	SoldNo plan 5 parts	1,694,614	$23.05 average	$39.1M	9.4%	Form 4
Dec 16, 2025 – Dec 17, 2025	Keith S Manchester Director	SoldNo plan 5 parts	1,694,614	$23.05 average	$39.1M	9.4%	Form 4
Dec 16, 2025 – Dec 17, 2025	QVT Financial LP Large holder	SoldNo plan 5 parts	1,694,614	$23.05 average	$39.1M	9.4%	Form 4
Dec 15, 2025	Matthew Gline CEO	SoldNo plan 3 parts	1,740,000	$21.68 average	$37.7M	9.1%	Form 4

Oct 2810b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at $36.59
$7.32M
14% of stake
Oct 2010b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at avg $35.11
$7.02M
13% of stake
Oct 110b5-1 plan
Melissa B Epperly
Director · sold 17,750 at avg $36.10
641K
54% of stake
Sep 3010b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at $36.62
$7.32M
11% of stake
Sep 1510b5-1 plan
Melissa B Epperly
Director · sold 4,938 at avg $39.74
196K
33% of stake
Sep 1510b5-1 plan
Meghan Fitzgerald
Director · sold 5,112 at avg $39.74
203K
12% of stake
Sep 810b5-1 plan
Meghan Fitzgerald
Director · sold 20,000 at $39.90
798K
32% of stake
Aug 2810b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at avg $35.77
$7.15M
11% of stake
Aug 19 – 21No plan
Mayukh Sukhatme
President & CIO · sold 335,174 at avg $36.88
$12.4M
1.8% of stake
Aug 14 – 18No plan
Mayukh Sukhatme
President & CIO · sold 664,826 at avg $36.34
$24.2M
3.4% of stake
Jul 2710b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at $34.95
$6.99M
11% of stake
Jun 3010b5-1 plan
Meghan Fitzgerald
Director · sold 10,000 at $34.90
349K
19% of stake
Jun 26 – 30No plan
Keith S Manchester
Director · sold 1,638,163 at avg $34.46
$56.4M
9.6% of stake
Jun 26 – 30No plan
Daniel Allen Gold
Director · sold 1,438,163 at avg $34.32
$49.4M
9.5% of stake
Jun 26 – 30No plan
QVT Financial LP
Large holder · sold 1,438,163 at avg $34.32
$49.4M
9.5% of stake
Jun 2910b5-1 plan
Melissa B Epperly
Director · sold 17,750 at avg $34.38
610K
52% of stake
Jun 25 – 26No plan
Mayukh Sukhatme
President & CIO · sold 1,000,000 at avg $34.11
$34.1M
5.1% of stake
Jun 2410b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at avg $33.16
$6.63M
11% of stake
May 2210b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at $30.27
$6.05M
11% of stake
Apr 2010b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at $29.59
$5.92M
11% of stake
Apr 16No plan
Matthew Gline
CEO · sold 289,774 at $29.16
$8.45M
1.7% of stake
Apr 8No plan
Jennifer Humes
Chief Accounting Officer · sold 13,538 at $28.37
384K
14% of stake
Mar 26No plan
Meghan Fitzgerald
Director · sold 70,000 at $27.45
$1.92M
62% of stake
Mar 1710b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at $28.24
$5.65M
11% of stake
Mar 16No plan
Melissa B Epperly
Director · sold 41,861 at $28.68
$1.2M
73% of stake
Feb 19 – 2310b5-1 plan
Frank Torti
President and Vant Chair · sold 3,000,000 at avg $27.35
$82M
18% of stake
Feb 1310b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at $26.49
$5.3M
11% of stake
Feb 11 – 13No plan
Keith S Manchester
Director · sold 1,225,784 at avg $26.64
$32.7M
7.5% of stake
Feb 11 – 13No plan
Daniel Allen Gold
Director · sold 1,225,784 at avg $26.64
$32.7M
7.5% of stake
Feb 11 – 13No plan
QVT Financial LP
Large holder · sold 1,225,784 at avg $26.64
$32.7M
7.5% of stake
Feb 9No plan
Mayukh Sukhatme
President & CIO · sold 339,441 at $26.47
$8.99M
1.8% of stake
Jan 1210b5-1 plan
Eric Venker
President & Immunovant CEO · sold 200,000 at $21.92
$4.38M
11% of stake
Dec 29, 2025 – Dec 31, 2025No plan
Mayukh Sukhatme
President & CIO · sold 1,330,868 at avg $21.72
$28.9M
6.6% of stake
Dec 23, 2025 – Dec 24, 2025No plan
Eric Venker
President & Immunovant CEO · sold 275,000 at avg $22.47
$6.18M
14% of stake
Dec 23, 2025No plan
Richard Pulik
CFO · sold 406,731 at avg $22.43
$9.12M
63% of stake
Dec 17, 2025No plan
Mayukh Sukhatme
President & CIO · sold 26,831 at $23.09
620K
0.1% of stake
Dec 16, 2025 – Dec 17, 2025No plan
Daniel Allen Gold
Director · sold 1,694,614 at avg $23.05
$39.1M
9.4% of stake
Dec 16, 2025 – Dec 17, 2025No plan
Keith S Manchester
Director · sold 1,694,614 at avg $23.05
$39.1M
9.4% of stake
Dec 16, 2025 – Dec 17, 2025No plan
QVT Financial LP
Large holder · sold 1,694,614 at avg $23.05
$39.1M
9.4% of stake
Dec 15, 2025No plan
Matthew Gline
CEO · sold 1,740,000 at avg $21.68
$37.7M
9.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ROIV, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ROIV

CompareIntrinsic value

KYNBKyntra Bio, Inc.

$3.96-8.12%20

ADAGAdagene Inc.

$2.41+2.55%25

COYACoya Therapeutics Inc.

$3.08-0.96%10

OVIDOvid Therapeutics Inc.

$2.74+14.17%25

NAMSNewAmsterdam Pharma Co. N.V.

$20.93+5.18%10

ACRSAclaris Therapeutics, Inc.

$3.68-1.60%10

ALMSAlumis Inc.

$6.55+0.77%10

HCWBHCW Biologics Inc.

$1.08-6.09%15

Held by ETFs

ROIV is in 142 US ETFs. The largest of them, with ROIV's weight in each:

Spot a number that looks wrong? Check it in ROIV's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ROIV

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.